David Adrian Ewald

David Adrian Ewald

Auto-generated profile, based on publicly available information

David Adrian Ewald

Explorative Biology and Bioinformatics, LEO Pharma, Ballerup, Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MSMayte Suárez-Fariñas
Mayte Suárez-Fariñas
BUBenjamin Ungar
Benjamin Ungar
JRJoel M. Correa da Rosa
Joel M. Correa da Rosa
DEDavid A. Ewald
David A. Ewald
MRMariya Rozenblit
Mariya Rozenblit
EGEmma Guttman-Yassky
Emma Guttman-Yassky

1 January 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
HEHitokazu Esaki
Hitokazu Esaki
DEDavid A. Ewald
David A. Ewald
BUBenjamin Ungar
Benjamin Ungar
MRMariya Rozenblit
Mariya Rozenblit
XZXiuzhong Zheng
Xiuzhong Zheng
EGEmma Guttman-Yassky
Emma Guttman-Yassky

12 October 2015 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
DEDavid A. Ewald
David A. Ewald
DMDana Malajian
Dana Malajian
JKJames G. Krueger
James G. Krueger
CWChristopher T. Workman
Christopher T. Workman
TWTianjiao Wang
Tianjiao Wang
MSMayte Suárez-Fariñas
Mayte Suárez-Fariñas
Atopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic disease phenotype. Although these experiments have shed light on disease pathology, inter-study comparisons reveal large differences in resulting sets of differentially expressed genes (DEGs), limiting the utility of direct comparisons across studies. We carried out a meta-analysis combining 4 published AD datasets to define a robust disease profile, termed meta-analysis derived AD (MADAD) transcriptome. This transcriptome enriches key AD pathways more than the individual studies, and associates AD with novel pathways, such as atherosclerosis signaling (IL-37, selectin E/SELE). We identified wide lipid abnormalities and, for the first time in vivo, correlated Th2 immune activation with downregulation of key epidermal lipids (FA2H, FAR2, ELOVL3), emphasizing the role of cytokines on the barrier disruption in AD. Key AD “classifier genes” discriminate lesional from nonlesional skin, and may evaluate therapeutic responses. Our meta-analysis provides novel and powerful insights into AD disease pathology, and reinforces the concept of AD as a systemic disease.

2 April 2018 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
MLMaria Louise Leth
Maria Louise Leth
MEMorten Ejby
Morten Ejby
CWChristopher T. Workman
Christopher T. Workman
DEDavid Adrian Ewald
David Adrian Ewald
SPSigne Schultz Pedersen
Signe Schultz Pedersen
MHMaher Abou Hachem
Maher Abou Hachem
Metabolism of dietary glycans is pivotal in shaping the human gut microbiota. However, the mechanisms that promote competition for glycans among gut commensals remain unclear. Roseburia intestinalis, an abundant butyrate-producing Firmicute, is a key degrader of the major dietary fibre xylan. Despite the association of this taxon to a healthy microbiota, insight is lacking into its glycan utilization machinery. Here, we investigate the apparatus that confers R. intestinalis growth on different xylans. R. intestinalis displays a large cell-attached modular xylanase that promotes multivalent and dynamic association to xylan via four xylan-binding modules. This xylanase operates in concert with an ATP-binding cassette transporter to mediate breakdown and selective internalization of xylan fragments. The transport protein of R. intestinalis prefers oligomers of 4–5 xylosyl units, whereas the counterpart from a model xylan-degrading Bacteroides commensal targets larger ligands. Although R. intestinalis and the Bacteroides competitor co-grew in a mixed culture on xylan, R. intestinalis dominated on the preferred transport substrate xylotetraose. These findings highlight the differentiation of capture and transport preferences as a possible strategy to facilitate co-growth on abundant dietary fibres and may offer a unique route to manipulate the microbiota based on glycan transport preferences in therapeutic interventions to boost distinct taxa.

1 February 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
DEDavid A. Ewald
David A. Ewald
SNShinji Noda
Shinji Noda
MOMargeaux Oliva
Margeaux Oliva
Thomas LitmanThomas Litman
Thomas Litman
SNSaeko Nakajima
Saeko Nakajima
EGEmma Guttman-Yassky
Emma Guttman-Yassky
Atopic dermatitis (AD) is caused by a complex interplay between immune and barrier abnormalities. Murine models of AD are essential for preclinical assessments of new treatments. Although many models have been used to simulate AD, their transcriptomic profiles are not fully understood, and a comparison of these models with the human AD transcriptomic fingerprint is lacking. We sought to evaluate the transcriptomic profiles of 6 common murine models and determine how they relate to human AD skin. Transcriptomic profiling was performed by using microarrays and quantitative RT-PCR on biopsy specimens from NC/Nga, flaky tail, Flg-mutated, ovalbumin-challenged, oxazolone-challenged, and IL-23-injected mice. Gene expression data of patients with AD, psoriasis, and contact dermatitis were obtained from previous patient cohorts. Criteria of a fold change of 2 or greater and a false discovery rate of 0.05 or less were used for gene arrays. IL-23-injected, NC/Nga, and oxazolone-challenged mice show the largest homology with our human meta-analysis-derived AD transcriptome (37%, 18%, 17%, respectively). Similar to human AD, robust TH1, TH2, and also TH17 activation are seen in IL-23-injected and NC/Nga mice, with similar but weaker inflammation in ovalbumin-challenged mice. Oxazolone-challenged mice show a TH1-centered reaction, and flaky tail mice demonstrate a strong TH17 polarization. Flg-mutated mice display filaggrin downregulation without significant inflammation. No single murine model fully captures all aspects of the AD profile; instead, each model reflects different immune or barrier disease aspects. Overall, among the 6 murine models, IL-23-injected mice best simulate human AD; still, the translational focus of the investigation should determine which model is most applicable.

1 March 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LTLewis E. Tomalin
Lewis E. Tomalin
CRChris B. Russell
Chris B. Russell
SGSandra Garcet
Sandra Garcet
DEDavid Adrian Ewald
David Adrian Ewald
PKPaul Klekotka
Paul Klekotka
JKJames G. Krueger
James G. Krueger